US biotech Amgen (Nasdaq: AMGN) and Ireland-incorporated drugmaker Allergan (NYSE: AGN) became the first to receive regulatory approval to market a biosimilar referencing a cancer drug in the USA on Tuesday.
Their copycat of Avastin (bevacizumab), a drug used for certain colorectal, lung, brain, kidney and cervical cancers that is marketed by Swiss pharma giant Roche (ROG: SIX), has been approved by the US Food and Drug Administration (FDA).
Avastin had global sales of 6.78 billion Swiss francs ($7.02 billion) in 2016, a total bettered by only one other cancer drug, namely Roche’s MabThera/Rituxan (rituximab).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze